[EDITORS/REPORTERS: You are invited to attend this special journalists-only lunch with David Nanus, Brian Kirby and Evi Giannakakou. To RSVP, please contact Blaine Friedlander at (607) 254-8093 or [email protected]]
Newswise — Cancer metastasis accounts for the majority of cancer-related deaths owing to poor response from anticancer therapies. Now, Cornell University researchers – both in Ithaca and the Weill Cornell Medical College in New York – have created a device that combs blood for living, circulating tumor cells. This new, microfluidic device allows doctors to monitor drug response at the cellular level, in real time, in order to tailor cancer therapies to the individual.
On Tuesday, June 12, from noon to 1:30 p.m., at the Weill Cornell Medical College in Manhattan, David Nanus, M.D., chief of the Division of Hematology and Medical Oncology at Weill Cornell Medical College; Brian Kirby, Ph.D., Cornell professor of mechanical and aerospace engineering; and Evi Giannakakou, Ph.D., associate professor of pharmacology and director of laboratory research in the Division of Hematology and Medical Oncology at Weill Cornell Medical College, will explain their new device. Following lunch, journalists will tour the Giannakakou laboratory for a demonstration. (The device will soon go into clinical trial.)
This is one of several joint Ithaca-New York City projects associated with the Cornell Center for Microenvironment and Metastasis, a $13 million National Institutes of Health-funded Physical Sciences-Oncology Center created to use physical techniques and processes to improve understanding and care of metastatic cancer in patients.
About Inside Cornell: This event is part of a monthly series held in New York City featuring high-interest experts working at Cornell University's centers in Manhattan, Ithaca and around the world. The free, catered lunch sessions are on-the-record, and media members are welcome to record video and audio as desired.
RSS